CTLA4 and metastatic melanoma: As the first ICPI, ipilimumab, which can block cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma in 2011 [7, 8].